{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:28:16Z","timestamp":1770985696659,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.vaccine.2012.11.096","type":"journal-article","created":{"date-parts":[[2012,12,13]],"date-time":"2012-12-13T04:04:10Z","timestamp":1355371450000},"page":"943-949","source":"Crossref","is-referenced-by-count":73,"title":["A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"Susan F.","family":"Slovin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marissa","family":"Kehoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Durso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celina","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian P.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Israel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard I.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.11.096_bib0120","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0125","first-page":"1099","article-title":"Overall survival analysis of a randomized phase II controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0130","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymthe.2005.02.012","article-title":"GM-CSF gene-transduced tumor vaccines","volume":"12","author":"Eager","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0135","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(12)70007-4","article-title":"Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial","volume":"13","author":"van den Eertwegh","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0025","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-10-1762","article-title":"Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy","volume":"17","author":"Stein","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0030","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/0042-6822(83)90124-1","article-title":"Protective monoclonal antibodies define maturational and pH-dependent antigenic changes in Sindbis virus E1 glycoprotein","volume":"130","author":"Schmaljohn","year":"1983","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0035","first-page":"10e33","article-title":"Therapeutic and prophylactic applications of alphavirus vectors","author":"Atkins","year":"2008","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0040","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.vaccine.2003.07.003","article-title":"Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes","volume":"22","author":"Cassetti","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0045","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1158\/1078-0432.CCR-06-2202","article-title":"A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses","volume":"13","author":"Durso","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0050","doi-asserted-by":"crossref","first-page":"8114","DOI":"10.1158\/1078-0432.CCR-05-1410","article-title":"Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles","volume":"11","author":"Goldberg","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"November (48)","key":"10.1016\/j.vaccine.2012.11.096_bib0055","doi-asserted-by":"crossref","first-page":"8180","DOI":"10.1016\/j.vaccine.2007.09.038","article-title":"Development and preclinical evaluation of an alphavirus replicon vaccine for influenza","volume":"25","author":"Hubby","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/B:BREA.0000004373.09678.bb","article-title":"Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the \u2018self\u2019 tumor-associated antigen, neu, in a rat mammary tumor model","volume":"82","author":"Nelson","year":"2003","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.vaccine.2012.11.096_bib0065","doi-asserted-by":"crossref","first-page":"R145","DOI":"10.1186\/bcr962","article-title":"Alphavirus replicon particles containing the gene for HER2\/neu inhibit breast cancer growth and tumorigenesis","volume":"7","author":"Wang","year":"2005","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0070","first-page":"2674","article-title":"Prostate-Specific Membrane Antigen is produced in tumor-associated neovasculature","volume":"5","author":"Chang","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0075","first-page":"32","article-title":"Identification of T-cell epitopes using ELISpot and peptide pool arrays","volume":"94","author":"Tobery","year":"2004","journal-title":"Methods Mol Med"},{"issue":"297","key":"10.1016\/j.vaccine.2012.11.096_bib0080","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/297070a0","article-title":"Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis","volume":"6","author":"Schmaljohn","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0085","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.vaccine.2009.09.135","article-title":"Randomized, double blind, phase I trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers","volume":"28","author":"Bernstein","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0090","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/PPO.0b013e31823e69ac","article-title":"Circulating tumor cells as biomarkers: progress toward biomarker quantification","volume":"17","author":"Danila","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0095","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1172\/JCI42672","article-title":"An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer","volume":"120","author":"Morse","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.urolonc.2005.11.033","article-title":"Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer","volume":"24","author":"Bradford","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0105","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1158\/1535-7163.MCT-11-0191","article-title":"In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen","volume":"10","author":"Wang","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0110","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/cncr.24795","article-title":"Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer","volume":"116","author":"Tagawa","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2012.11.096_bib0115","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/973820","article-title":"Prostate-specific membrane antigen-based therapeutics","volume":"2012","author":"Akhtar","year":"2012","journal-title":"Adv Urol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12017471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12017471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T07:00:34Z","timestamp":1540018834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12017471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0264410X12017471"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.11.096","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}